Progress made in HIV vaccine development

Nov 16, 2006

U.S. researchers report successfully testing two candidate vaccines that may eventually be used together to protect against HIV infection.

Dr. Barney Graham and colleagues from the National Institutes of Health Vaccine Research Center, the Fred Hutchinson Cancer Research Center in Seattle, and GenVec Inc. tested two possible HIV vaccines with the hope of producing an immune response in healthy, uninfected adults.

One candidate was a plasmid DNA-based vaccine expressing genes from three dominant HIV subtypes, and the second used recombinant adenovirus serotype 5 (rAd5) as a vector to deliver similar HIV strains.

Both vaccines were tested in healthy, uninfected adult volunteers. The DNA vaccine was found safe and well-tolerated. By the 12th week following immunization, 97.5 percent of vaccinees experienced positive CD4 T cell responses and 40 percent experienced positive CD8 T cell responses.

The recombinant vector vaccine was also well-tolerated but higher doses led to adverse events such as pain and fever. By the fourth week following immunization, 93.3 percent of vaccinees experienced positive CD4 T cell responses, and 60 percent experienced positive CD8 T cell responses.

The study is detailed in the Dec. 15 issue of The Journal of Infectious Diseases.

Copyright 2006 by United Press International

Explore further: Investigational HIV vaccine regimen shows encouraging results in non-human primates

Related Stories

We must defend science if we want a prosperous future

Mar 03, 2015

Today's Australians are, by far, the best educated cohort in our history –- on paper, anyway -– but this is not reflected in the quality of our political discourse. We appear to be lacking in courage, ...

Vaccines from a reactor

Mar 02, 2015

In the event of an impending global flu pandemic, vaccine production could quickly reach its limits, as flu vaccines are still largely produced in embryonated chicken eggs. Udo Reichl, Director at the Max ...

Cool crystals and hot climates

Jan 16, 2015

A crystalline structure used by a silkworm virus to protect itself from the elements may provide similar protection for human vaccines in challenging tropical climates and remote regions.

Recommended for you

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.